ABCL News and Press, AbCellera Biologics Inc. From 05/13/21

AbCellera Biologics Inc. (ABCL) Q1 2021 Earnings Conference Call May 13, 2021 05:00 PM ET Company Participants Tryn Stimart - Chief Legal Officer & Chief Compliance Officer Carl Hansen - Chief Executive Officer & President Andrew Booth - Chief Financial Officer Conference Call Partici...

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2021 Q1 earnings call. For further details see: AbCellera Biologics Inc. 2021 Q1 - Results - Earnings Call Presentation

AbCellera Biologics (ABCL): Q1 GAAP EPS of $0.37 misses by $0.01.Revenue of $202.74M (+4260.0% Y/Y) beats by $3.39M.Total programs under contract of 119, up 63% year-over-yearAs of March 31, 2021, the Company had 119 discovery programs (up 63% from 73 on March 31, 2020) that are either comple...

Total revenue of $203 million, up from $5 million in Q1 2020 Total programs under contract of 119, up 63% year-over-year EPS of $0.43 (basic) and $0.37 (diluted) compared to $0.01 loss per share in Q1 2020 AbCellera (Nasdaq: ABCL), a technology company wi...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the Berenberg Conference USA 2021 on Tuesday, May 18, 2021 at 11:00 a.m. Pacific Time. A live audio webcast of the presentation may be accessed through a link that will be posted on ...

AbCellera (ABCL) and Angios GmbH have entered into a multi-year, multi-target collaboration for the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye.Under the deal, AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels o...

Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target ...

AbCellera ([[ABCL]] +0.8%) announced the preclinical data highlighting the efficacy of LY-CoV1404 a second antibody developed as part of its collaboration with Eli Lilly ([[LLY]] +1.2%).The new preclinical data have demonstrated that LY-CoV1404 can bind and neutralize ‘all cu...

- New preclinical data show that LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern - LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting effectiveness against emerging variants - LY-C...

I operate two main portfolios: my "safe" portfolio and my high growth portfolio. This article will dissect and focus on my high-growth holdings. I generally like to invest in themes and tend to take a shotgun approach to my holdings in emerging sectors. I will list my holdings for 8 s...